KRAS G13D-IN-2 (compound 8B) is a potent orally active KRAS G13D inhibitor with IC50 values of 1.95 µM (HCT-116G13D) and 2.16 µM (HCT-15G13D). KRAS G13D-IN-2 induces G1-phase arrest and mitochondrial membrane depolarization. KRAS G13D-IN-2 induces senescence through CDK6/TWIST1 inhibition. KRAS G13D-IN-2 inhibits tumor growth in murine models. KRAS G13D-IN-2 can be used for KRASG13D-mutant colorectal cancer research[1].
Molecular Weight:
584.87
Formula:
C36H60N2O4
Target:
CDK,Mitochondrial Metabolism,Ras
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
